MedTrace Logo

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

NCT00002663 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-02-13

Study results available
· View outcomes & findings →

Summary

The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.

Conditions

  • EBV-induced Lymphomas
  • EBV-associated Malignancies
  • Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

Interventions

BIOLOGICAL

Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)

EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Sponsors & Collaborators

Principal Investigators

  • Minoti Hiremath, MD · Atara Biotherapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-03-31
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002663 on ClinicalTrials.gov